Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,430.00
-400.00 (-4.53%)
Mar 28, 2025, 3:30 PM KST
-60.70%
Market Cap 193.83B
Revenue (ttm) 1.90B
Net Income (ttm) -10.62B
Shares Out 22.99M
EPS (ttm) -463.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,410
Average Volume 108,606
Open 8,830.00
Previous Close 8,830.00
Day's Range 8,420.00 - 8,830.00
52-Week Range 8,420.00 - 25,200.00
Beta 3.38
RSI 32.22
Earnings Date n/a

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements

News

There is no news available yet.